go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Bayer Limited

Bayer Limited
The Atrium, Blackthorn Road, Dublin 18,
Telephone: +353 1 2999 313
Fax: +353 1 2061 456
Summary of Product Characteristics last updated on medicines.ie: 01/07/2010
SPC Nimotop 0.02% w/v Concentrate for Solution for Infusion.

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 01/07/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   21-Jun-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Please note where new text has been inserted into a sentence the text has been highlighted  in red:

 

1.         NAME OF THE MEDICINAL PRODUCT

 

Nimotop 0.02% w/v Concentrate for Solution for Infusion.

 

 

2.         QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Addition of:

“Each 50ml vial also contains 10g of ethanol (0.2g/ml) and 2.3mg of sodium (as sodium citrate dihydrate).”

 

For a full list of excipients, see 6.1.

 

 

3.         PHARMACEUTICAL FORM

 

            Concentrate for solution for infusion (Sterile concentrate).

 

            A clear, yellow solution.

 

 

4.2       Posology and method of administration

 

Therapeutic administration

 

Subsection: Route of administration

“Nimotop solution must not be added to an infusion bag or bottle and msut not be moixed with other drugs.”  has been changed to:

 

“Nimotop must not be mixed with other drugs so it should not be added to an infusion bag or bottle which contains other drugs.” 

 

 

4.4       Special warnings and precautions for use

 

At the end of this section addition of “Nimotop should not be used in concentrated form.”

 

 

6.2              Incompatibilities

 

Addition of “Nimotop must not be mixed with other drugs so it should not be added to an infusion bag or bottle which contains other drugs.”

 

 

6.4       Special precautions for storage

 

            Do not store above 25°C.  Keep the vial in the outer carton to protect from light.

 

 

9.         DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION

 

Date of first authorisation:          15 February 1994

Date of last renewal:     15 Feburary 2009

 

 

10.       DATE OF REVISION OF THE TEXT

Changed to “June 2010”

Updated on 16/10/2008 and displayed until 01/07/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   12/1007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Change to MA Holder, MA Number and date of revision of text.
Updated on 17/05/2007 and displayed until 16/10/2008
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   11/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Sections 4.2, 5.1, 5.2, 5.3 and 6.6 where updated following internal review.

Updated on 23/05/2005 and displayed until 17/05/2007
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 06/12/2004 and displayed until 23/05/2005
Reasons for adding or updating:
  • Change to section 6.5 - Nature and contents of container
Updated on 03/12/2004 and displayed until 06/12/2004
Reasons for adding or updating:
  • Change to section 10 - Date of revision of the text
Updated on 29/05/2003 and displayed until 03/12/2004
Reasons for adding or updating:
  • New SPC for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Nimodipine

Versions

 
01/07/2010 to Current
16/10/2008 to 01/07/2010
17/05/2007 to 16/10/2008
23/05/2005 to 17/05/2007
06/12/2004 to 23/05/2005
03/12/2004 to 06/12/2004
29/05/2003 to 03/12/2004
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo